1.
J Dermatol
; 47(11): e414-e415, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32748954
2.
J Dermatol
; 47(10): e356-e357, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32677069
3.
J Dermatol
; 46(1): e38-e39, 2019 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29952018
Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Mucosite/tratamento farmacológico , Mycoplasma pneumoniae/isolamento & purificação , Pneumonia por Mycoplasma/tratamento farmacológico , Estomatite/tratamento farmacológico , Adulto , Testes de Aglutinação , Diagnóstico Diferencial , Feminino , Humanos , Infusões Intravenosas , Mucosite/diagnóstico , Mucosite/microbiologia , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/microbiologia , Síndrome de Stevens-Johnson/diagnóstico , Estomatite/diagnóstico , Estomatite/microbiologia , Resultado do Tratamento
4.
J Dermatol
; 45(5): 600-602, 2018 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29446164
RESUMO
Bullous pemphigoid (BP) is a common autoimmune blistering disorder with unknown etiology. Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase-4 inhibitors (DPP4i), widely used antihyperglycemic drugs, have been reported in published works. Here, we report a case of DPP4i (teneligliptin)-associated BP that developed in a 70-year-old Japanese man. Interestingly, the patient had acquired reactive perforating collagenosis (ARPC), which is also known to be associated with the onset of BP. In the present case, clinical, histopathological and immunological findings suggested that DPP4i rather than ARPC was associated with the onset of BP.